US-based Sherpa Clinical Packaging has made an undisclosed investment to add a new manufacturing plant adjacent to its headquarters in San Diego, California.The 24,000ft² facility will support Sherpa’s packaging, labelling, and distribution services.
The building will feature four packaging suites, a class 100,000 cleanroom, and various temperature-controlled storage areas, including a warehouse.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Construction of the facility has already started, with plans to complete the same by July this year.
Sherpa Clinical Packaging president and founder Mark Paiz said: “I am extremely pleased to see so many of our customers moving into Phase II and III clinical trials.
“As the number of global clinical trials that Sherpa supports increases over the next few years, Sherpa’s expanded clinical supply offerings, partnerships and facilities are well poised to support this growth.”
The company is further planning to include more resources in its operations, quality, and project management teams within the next year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSherpa currently provides clinical trial material management services for use in clinical studies Phases I-IV, including packaging, labelling, distribution and returns / reconciliation, for pharmaceutical, biotechnology, medical device and dietary supplement companies.
The company supplies its products to several clinical trials sites across the US, Canada and European countries.
In September 2016, Sherpa installed a new blister packaging machine at its facility in San Diego.
Image: Sherpa Clinical Packaging headquarters in San Diego, California, US. Photo: courtesy of Sherpa Clinical Packaging.
